Economic Impact of Faricimab in Neovascular Age-Related Macular Degeneration Management in France
Author(s)
Sarah Akarkoub, MSc1, Chloe Gerves-Pinquie, PhD1, Marguerite Kandel, PhD1, Sophie PIBRE, MASc2, Sandy Leproust, PhD1, KATELL LE LAY, MSc2, Margaux AZAR, PharmD2, Roula Ajjouri, MBA2.
1IQVIA, Courbevoie, France, 2Roche, Boulogne-Billancourt, France.
1IQVIA, Courbevoie, France, 2Roche, Boulogne-Billancourt, France.
OBJECTIVES: To assess the budget impact in France of the introduction of Faricimab into the current therapeutic strategy for patients with neovascular (wet) age-related macular degeneration (nAMD).
METHODS: The model estimated the impact of the introduction of Faricimab into the current therapeutic strategy, including all reimbursed anti-VEGF therapies for nAMD, from the French payer perspective. The target population was estimated using epidemiological estimation from the HEMERA study, a retrospective study based on the French national health data system (SNDS). Based on HEMERA results, direct medical costs were estimated, including acquisition costs and administration costs. A scenario analysis was also conducted from a societal perspective, integrating informal care costs (from literature), sick leaves, and out-of-pocket expenses.
RESULTS: Over a 5-year horizon, introducing Faricimab into the current treatment strategy for nAMD in France is projected to reduce total expenditures for the French payer perspective by 7%, corresponding to €1,914 in savings per treated patient, leading to an overall savings of €96.6 million. The key variable of the analysis was the number of intravitreal injections required per treatment: compared to other anti-VEGF therapies, Faricimab was associated with an average reduction of 0.74 injection in the first year and 1.01 injections annually in subsequent years. Most of the cost reduction is attributed to drug acquisition costs (75%), followed by administration costs (22%). From a societal perspective, total savings were estimated at €2,195 per patient over 5 years.
CONCLUSIONS: The integration of Faricimab into the therapeutic strategy for nAMD in France leads to substantial cost savings for the healthcare system. These savings are primarily driven by the reduced number of intravitreal injections required with Faricimab compared to other anti-VEGF therapies. Even moderately, the savings associated with the introduction of Faricimab are even greater when considered from a societal perspective.
METHODS: The model estimated the impact of the introduction of Faricimab into the current therapeutic strategy, including all reimbursed anti-VEGF therapies for nAMD, from the French payer perspective. The target population was estimated using epidemiological estimation from the HEMERA study, a retrospective study based on the French national health data system (SNDS). Based on HEMERA results, direct medical costs were estimated, including acquisition costs and administration costs. A scenario analysis was also conducted from a societal perspective, integrating informal care costs (from literature), sick leaves, and out-of-pocket expenses.
RESULTS: Over a 5-year horizon, introducing Faricimab into the current treatment strategy for nAMD in France is projected to reduce total expenditures for the French payer perspective by 7%, corresponding to €1,914 in savings per treated patient, leading to an overall savings of €96.6 million. The key variable of the analysis was the number of intravitreal injections required per treatment: compared to other anti-VEGF therapies, Faricimab was associated with an average reduction of 0.74 injection in the first year and 1.01 injections annually in subsequent years. Most of the cost reduction is attributed to drug acquisition costs (75%), followed by administration costs (22%). From a societal perspective, total savings were estimated at €2,195 per patient over 5 years.
CONCLUSIONS: The integration of Faricimab into the therapeutic strategy for nAMD in France leads to substantial cost savings for the healthcare system. These savings are primarily driven by the reduced number of intravitreal injections required with Faricimab compared to other anti-VEGF therapies. Even moderately, the savings associated with the introduction of Faricimab are even greater when considered from a societal perspective.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE398
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)